Loading
A phase 3 trial of Izalontamab brengitecan, Topotecan in small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) is a phase 3 interventional study registered as NCT06500026 by Sichuan Baili Pharmaceutical Co., Ltd., with 722 participants enrolled, started 2024-08-07 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1, Topotecan. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Small-cell lung cancer, Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer.